Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 22:25 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableEnrolling by invitationOBSERVATIONAL

GLP_1 RA Ultrasound Study

ClinicalTrials.gov · NCT06581120 · Registry updated: 2024-11-07

Condition / research focus: Glucagon Like Peptide-1 (GLP-1; Delayed Gastric Emptying; Risk of Aspiration; Diabetes; Morbid Obesity
Sponsor: Children's Hospital Medical Center, Cincinnati
Countries with listed sites: United States
Registry dates and results: Start: 2024-07-08. Completion: 2026-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon-Like Peptide-1 receptor agonists (drug)
Point of Care Gastric Ultrasound (diagnostic_test) — also listed as: POGUS

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Cincinnati Children's Hospital
Cincinnati, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

ClinicalTrials.gov · NCT04199728 · Registry updated: 2024-11-06

Condition / research focus: Opiate Substitution Treatment; Opioid-Related Disorders
Sponsor: Milton S. Hershey Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2021-10-18. Completion: 2023-09-13 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide Pen Injector (drug) — also listed as: Saxenda
Placebo (drug)

Where the study takes place — 1 listed sites

Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF

ClinicalTrials.gov · NCT06660134 · Registry updated: 2024-10-28

Condition / research focus: Type 2 Diabetes Mellitus (T2DM); Atrial Fibrillation (AF)
Sponsor: Shanghai Chest Hospital
Countries with listed sites: China
Registry dates and results: Start: 2021-08-01. Completion: 2024-01-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon-like peptide-1 receptor agonists (GLP 1 RA) (drug)

Where the study takes place — 1 listed sites

Shanghai Chest Hospital
Shanghai, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism

ClinicalTrials.gov · NCT04300049 · Registry updated: 2024-10-21

Condition / research focus: Insulin Sensitivity
Sponsor: The University of Texas Health Science Center at San Antonio
Countries with listed sites: United States
Registry dates and results: Start: 2018-02-05. Completion: 2023-11-15 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon Infusion (drug) — also listed as: IV Glucagon
Saline (other) — also listed as: Normal saline

Where the study takes place — 2 listed sites

South Texas Veterans Health Care Center
San Antonio, Texas, United States
Site recruitment: Not reported
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

GPR119 Agonist for Hypoglycemia in Type 1 Diabetes

ClinicalTrials.gov · NCT04432090 · Registry updated: 2024-10-17

Condition / research focus: Diabetes Mellitus, Type 1
Sponsor: AdventHealth Translational Research Institute
Countries with listed sites: United States
Registry dates and results: Start: 2021-04-21. Completion: 2023-08-12 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug) — also listed as: MBX-2982
Study Medication (MBX-2982) (drug) — also listed as: MBX-2982
No medication for this group (other)

Where the study takes place — 1 listed sites

AdventHealth Translational Research Institute
Orlando, Florida, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in Humans

ClinicalTrials.gov · NCT06647368 · Registry updated: 2024-10-17

Condition / research focus: Cerebral Glucose Metabolism
Sponsor: Nicolai Jacob Wewer Albrechtsen
Countries with listed sites: Denmark
Registry dates and results: Start: 2024-10-22. Completion: 2024-12-17 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PET with 18-FDG (other)

Where the study takes place — 1 listed sites

Department of Physiology and Nuclear Medicine, University of Copenhagen - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
Copenhagen, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

ClinicalTrials.gov · NCT05708859 · Registry updated: 2024-10-15

Condition / research focus: Type II Diabetes; Atherosclerosis
Sponsor: Matthew J. Budoff
Countries with listed sites: United States
Registry dates and results: Start: 2024-01-02. Completion: 2026-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Mounjaro
Placebo (drug)

Where the study takes place — 1 listed sites

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute)
Torrance, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices

ClinicalTrials.gov · NCT05810597 · Registry updated: 2024-10-15

Condition / research focus: Healthy
Sponsor: Eli Lilly and Company
Countries with listed sites: United States
Registry dates and results: Start: 2023-04-03. Completion: 2023-07-17 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Single Dose Pen (device)
Multi-use Prefilled Pen (device)

Where the study takes place — 3 listed sites

Qps-Mra, Llc
South Miami, Florida, United States
Site recruitment: Not reported
ICON Early Phase Services
San Antonio, Texas, United States
Site recruitment: Not reported
ICON
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

ClinicalTrials.gov · NCT05526157 · Registry updated: 2024-10-15

Condition / research focus: Chronic Kidney Disease; Type 2 Diabetes Mellitus
Sponsor: Bayer
Countries with listed sites: Denmark · Japan · Netherlands · Spain · United States
Registry dates and results: Start: 2022-10-01. Completion: 2024-09-05 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Finerenone (Kerendia, BAY 948862) (drug)
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) (drug)
Glucagon-like peptide-1 receptor agonists (GLP 1 RA) (drug)
Steroidal mineral corticoid receptor antagonists (sMRA) (drug)
Non-steroidal mineral corticoid receptor antagonists (nsMRA) (drug)

Where the study takes place — 5 listed sites

Optum CDM
Eden Prairie, Minnesota, United States
Site recruitment: Not reported
Many Locations
Multiple Locations, Denmark
Site recruitment: Not reported
Many Locations
Multiple Locations, Japan
Site recruitment: Not reported
Many Locations
Multiple Locations, Netherlands
Site recruitment: Not reported
Many Locations
Multiple Locations, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Evaluating the Benefits of Physiologic Insulin Delivery

ClinicalTrials.gov · NCT04416737 · Registry updated: 2024-10-01

Condition / research focus: Type 1 Diabetes
Sponsor: Stanford University
Countries with listed sites: United States
Registry dates and results: Start: 2021-11-01. Completion: 2023-06-02 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ultra-rapid insulin (drug)

Where the study takes place — 1 listed sites

Stanford University
Stanford, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

ClinicalTrials.gov · NCT03115424 · Registry updated: 2024-09-27

Condition / research focus: Obesity
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2017-06-22. Completion: 2024-05-30 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda (drug) — also listed as: Liraglutide
Placebos (drug) — also listed as: Placebo for Saxenda (Liraglutide)
RYGB (procedure)

Where the study takes place — 1 listed sites

Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3WithdrawnINTERVENTIONAL

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

ClinicalTrials.gov · NCT04683237 · Registry updated: 2024-09-26

Condition / research focus: Atypical Endometrial Hyperplasia; Obese; Fertility Issues
Sponsor: Xiaojun Chen
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-03-20. Completion: 2026-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide Injection (drug) — also listed as: victoza, Nuo he li
Megestrol Acetate 160 MG (drug) — also listed as: Yi li zhi, Megace

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

ClinicalTrials.gov · NCT04892199 · Registry updated: 2024-09-25

Condition / research focus: Metabolic Disturbance; Schizophrenia; Type 2 Diabetes; Clozapine; GLP-1; Olanzapine
Sponsor: Anders Fink-Jensen, MD, DMSci
Countries with listed sites: Denmark
Registry dates and results: Start: 2021-09-01. Completion: 2026-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide, 1.34 mg/mL (drug)
Semaglutide-placebo (drug)

Where the study takes place — 3 listed sites

Psychosis Research Unit, Aarhus University Hospital, Psychiatry,
Aarhus, Denmark
Site recruitment: Not reported
Psychiatric Centre Copenhagen, Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Psychiatric Centre Nordsjaelland, Hillerød
Hillerød, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.

ClinicalTrials.gov · NCT06601517 · Registry updated: 2024-09-23

Condition / research focus: Healthy Adult Subject; Overweight Subject
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-10. Completion: 2025-04 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Repaglinide (drug)
Atorvastatin (drug)
Digoxin (drug)
Rosuvastatin (drug)
HDM1002 (drug)

Where the study takes place — 1 listed sites

Peking University Third Hospital
Beijing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects

ClinicalTrials.gov · NCT06608329 · Registry updated: 2024-09-23

Condition / research focus: Healthy Adult Subject
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-10. Completion: 2024-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HDM1002 (drug)

Where the study takes place — 1 listed sites

Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

ClinicalTrials.gov · NCT04531176 · Registry updated: 2024-09-19

Condition / research focus: Type 2 Diabetes; Obesity
Sponsor: The Cleveland Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2020-09-01. Completion: 2023-08-04 (may be estimated). Results are posted in this registry.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Weight Management Program (WMP) (other)
Traditional care (other)
Phentermine / Topiramate Extended Release Oral Capsule (drug)
naltrexone/bupropion extended-release (drug)
liraglutide 3.0 mg (drug)
Orlistat (drug)

Where the study takes place — 1 listed sites

Cleveland Clinic
Cleveland, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes

ClinicalTrials.gov · NCT04307797 · Registry updated: 2024-09-19

Condition / research focus: Type 2 Diabetes; Obesity
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2022-01-18. Completion: 2022-10-07 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

0.9% Sodium-chloride (drug)
Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min (drug) — also listed as: Byetta
Glucagon 12.5ng/kg/min and 0.9% saline (drug)
0.9% Sodium-chloride (drug)
Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min (drug)
Glucagon 12.5ng/kg/min (drug)

Where the study takes place — 1 listed sites

Cambridge University Hospitals NHS Foundation Trust and The University of Cambridge
Cambridge, Cambridgeshire, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects

ClinicalTrials.gov · NCT06576401 · Registry updated: 2024-09-04

Condition / research focus: Healthy Adult Subject
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-08-27. Completion: 2024-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

[14C] HDM1002 (drug)

Where the study takes place — 1 listed sites

The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes

ClinicalTrials.gov · NCT05973799 · Registry updated: 2024-09-03

Condition / research focus: Hypoglycemia; Type1diabetes
Sponsor: University of Cincinnati
Countries with listed sites: United States
Registry dates and results: Start: 2019-10-10. Completion: 2024-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Fasting (other)
Feeding (other)

Where the study takes place — 1 listed sites

University of Cincinnati
Cincinnati, Ohio, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

ClinicalTrials.gov · NCT06099067 · Registry updated: 2024-08-30

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: Sweden
Registry dates and results: Start: 2020-05-15. Completion: 2023-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Canagliflozin (drug)
DPP4 inhibitor (drug)
Liraglutide (drug)
Saxagliptin (drug)
2nd generation Sulfonylurea (drug)

Where the study takes place — 1 listed sites

Research Site
Gothenburg, Sweden
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 22:25 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableEnrolling by invitationOBSERVATIONAL

GLP_1 RA Ultrasound Study

ClinicalTrials.gov · NCT06581120 · Registry updated: 2024-11-07

Condition / research focus: Glucagon Like Peptide-1 (GLP-1; Delayed Gastric Emptying; Risk of Aspiration; Diabetes; Morbid Obesity
Sponsor: Children's Hospital Medical Center, Cincinnati
Countries with listed sites: United States
Registry dates and results: Start: 2024-07-08. Completion: 2026-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon-Like Peptide-1 receptor agonists (drug)
Point of Care Gastric Ultrasound (diagnostic_test) — also listed as: POGUS

Where the study takes place — 1 listed sites

Cincinnati Children's Hospital
Cincinnati, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

ClinicalTrials.gov · NCT04199728 · Registry updated: 2024-11-06

Condition / research focus: Opiate Substitution Treatment; Opioid-Related Disorders
Sponsor: Milton S. Hershey Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2021-10-18. Completion: 2023-09-13 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide Pen Injector (drug) — also listed as: Saxenda
Placebo (drug)

Where the study takes place — 1 listed sites

Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF

ClinicalTrials.gov · NCT06660134 · Registry updated: 2024-10-28

Condition / research focus: Type 2 Diabetes Mellitus (T2DM); Atrial Fibrillation (AF)
Sponsor: Shanghai Chest Hospital
Countries with listed sites: China
Registry dates and results: Start: 2021-08-01. Completion: 2024-01-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon-like peptide-1 receptor agonists (GLP 1 RA) (drug)

Where the study takes place — 1 listed sites

Shanghai Chest Hospital
Shanghai, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism

ClinicalTrials.gov · NCT04300049 · Registry updated: 2024-10-21

Condition / research focus: Insulin Sensitivity
Sponsor: The University of Texas Health Science Center at San Antonio
Countries with listed sites: United States
Registry dates and results: Start: 2018-02-05. Completion: 2023-11-15 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon Infusion (drug) — also listed as: IV Glucagon
Saline (other) — also listed as: Normal saline

Where the study takes place — 2 listed sites

South Texas Veterans Health Care Center
San Antonio, Texas, United States
Site recruitment: Not reported
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

GPR119 Agonist for Hypoglycemia in Type 1 Diabetes

ClinicalTrials.gov · NCT04432090 · Registry updated: 2024-10-17

Condition / research focus: Diabetes Mellitus, Type 1
Sponsor: AdventHealth Translational Research Institute
Countries with listed sites: United States
Registry dates and results: Start: 2021-04-21. Completion: 2023-08-12 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug) — also listed as: MBX-2982
Study Medication (MBX-2982) (drug) — also listed as: MBX-2982
No medication for this group (other)

Where the study takes place — 1 listed sites

AdventHealth Translational Research Institute
Orlando, Florida, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in Humans

ClinicalTrials.gov · NCT06647368 · Registry updated: 2024-10-17

Condition / research focus: Cerebral Glucose Metabolism
Sponsor: Nicolai Jacob Wewer Albrechtsen
Countries with listed sites: Denmark
Registry dates and results: Start: 2024-10-22. Completion: 2024-12-17 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PET with 18-FDG (other)

Where the study takes place — 1 listed sites

Department of Physiology and Nuclear Medicine, University of Copenhagen - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
Copenhagen, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

ClinicalTrials.gov · NCT05708859 · Registry updated: 2024-10-15

Condition / research focus: Type II Diabetes; Atherosclerosis
Sponsor: Matthew J. Budoff
Countries with listed sites: United States
Registry dates and results: Start: 2024-01-02. Completion: 2026-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Mounjaro
Placebo (drug)

Where the study takes place — 1 listed sites

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute)
Torrance, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices

ClinicalTrials.gov · NCT05810597 · Registry updated: 2024-10-15

Condition / research focus: Healthy
Sponsor: Eli Lilly and Company
Countries with listed sites: United States
Registry dates and results: Start: 2023-04-03. Completion: 2023-07-17 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Single Dose Pen (device)
Multi-use Prefilled Pen (device)

Where the study takes place — 3 listed sites

Qps-Mra, Llc
South Miami, Florida, United States
Site recruitment: Not reported
ICON Early Phase Services
San Antonio, Texas, United States
Site recruitment: Not reported
ICON
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

ClinicalTrials.gov · NCT05526157 · Registry updated: 2024-10-15

Condition / research focus: Chronic Kidney Disease; Type 2 Diabetes Mellitus
Sponsor: Bayer
Countries with listed sites: Denmark · Japan · Netherlands · Spain · United States
Registry dates and results: Start: 2022-10-01. Completion: 2024-09-05 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Finerenone (Kerendia, BAY 948862) (drug)
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) (drug)
Glucagon-like peptide-1 receptor agonists (GLP 1 RA) (drug)
Steroidal mineral corticoid receptor antagonists (sMRA) (drug)
Non-steroidal mineral corticoid receptor antagonists (nsMRA) (drug)

Where the study takes place — 5 listed sites

Optum CDM
Eden Prairie, Minnesota, United States
Site recruitment: Not reported
Many Locations
Multiple Locations, Denmark
Site recruitment: Not reported
Many Locations
Multiple Locations, Japan
Site recruitment: Not reported
Many Locations
Multiple Locations, Netherlands
Site recruitment: Not reported
Many Locations
Multiple Locations, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Evaluating the Benefits of Physiologic Insulin Delivery

ClinicalTrials.gov · NCT04416737 · Registry updated: 2024-10-01

Condition / research focus: Type 1 Diabetes
Sponsor: Stanford University
Countries with listed sites: United States
Registry dates and results: Start: 2021-11-01. Completion: 2023-06-02 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ultra-rapid insulin (drug)

Where the study takes place — 1 listed sites

Stanford University
Stanford, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

ClinicalTrials.gov · NCT03115424 · Registry updated: 2024-09-27

Condition / research focus: Obesity
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2017-06-22. Completion: 2024-05-30 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda (drug) — also listed as: Liraglutide
Placebos (drug) — also listed as: Placebo for Saxenda (Liraglutide)
RYGB (procedure)

Where the study takes place — 1 listed sites

Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3WithdrawnINTERVENTIONAL

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

ClinicalTrials.gov · NCT04683237 · Registry updated: 2024-09-26

Condition / research focus: Atypical Endometrial Hyperplasia; Obese; Fertility Issues
Sponsor: Xiaojun Chen
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-03-20. Completion: 2026-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide Injection (drug) — also listed as: victoza, Nuo he li
Megestrol Acetate 160 MG (drug) — also listed as: Yi li zhi, Megace

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

ClinicalTrials.gov · NCT04892199 · Registry updated: 2024-09-25

Condition / research focus: Metabolic Disturbance; Schizophrenia; Type 2 Diabetes; Clozapine; GLP-1; Olanzapine
Sponsor: Anders Fink-Jensen, MD, DMSci
Countries with listed sites: Denmark
Registry dates and results: Start: 2021-09-01. Completion: 2026-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide, 1.34 mg/mL (drug)
Semaglutide-placebo (drug)

Where the study takes place — 3 listed sites

Psychosis Research Unit, Aarhus University Hospital, Psychiatry,
Aarhus, Denmark
Site recruitment: Not reported
Psychiatric Centre Copenhagen, Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Psychiatric Centre Nordsjaelland, Hillerød
Hillerød, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.

ClinicalTrials.gov · NCT06601517 · Registry updated: 2024-09-23

Condition / research focus: Healthy Adult Subject; Overweight Subject
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-10. Completion: 2025-04 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Repaglinide (drug)
Atorvastatin (drug)
Digoxin (drug)
Rosuvastatin (drug)
HDM1002 (drug)

Where the study takes place — 1 listed sites

Peking University Third Hospital
Beijing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects

ClinicalTrials.gov · NCT06608329 · Registry updated: 2024-09-23

Condition / research focus: Healthy Adult Subject
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-10. Completion: 2024-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HDM1002 (drug)

Where the study takes place — 1 listed sites

Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

ClinicalTrials.gov · NCT04531176 · Registry updated: 2024-09-19

Condition / research focus: Type 2 Diabetes; Obesity
Sponsor: The Cleveland Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2020-09-01. Completion: 2023-08-04 (may be estimated). Results are posted in this registry.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Weight Management Program (WMP) (other)
Traditional care (other)
Phentermine / Topiramate Extended Release Oral Capsule (drug)
naltrexone/bupropion extended-release (drug)
liraglutide 3.0 mg (drug)
Orlistat (drug)

Where the study takes place — 1 listed sites

Cleveland Clinic
Cleveland, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes

ClinicalTrials.gov · NCT04307797 · Registry updated: 2024-09-19

Condition / research focus: Type 2 Diabetes; Obesity
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2022-01-18. Completion: 2022-10-07 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

0.9% Sodium-chloride (drug)
Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min (drug) — also listed as: Byetta
Glucagon 12.5ng/kg/min and 0.9% saline (drug)
0.9% Sodium-chloride (drug)
Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min (drug)
Glucagon 12.5ng/kg/min (drug)

Where the study takes place — 1 listed sites

Cambridge University Hospitals NHS Foundation Trust and The University of Cambridge
Cambridge, Cambridgeshire, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects

ClinicalTrials.gov · NCT06576401 · Registry updated: 2024-09-04

Condition / research focus: Healthy Adult Subject
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-08-27. Completion: 2024-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

[14C] HDM1002 (drug)

Where the study takes place — 1 listed sites

The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes

ClinicalTrials.gov · NCT05973799 · Registry updated: 2024-09-03

Condition / research focus: Hypoglycemia; Type1diabetes
Sponsor: University of Cincinnati
Countries with listed sites: United States
Registry dates and results: Start: 2019-10-10. Completion: 2024-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Fasting (other)
Feeding (other)

Where the study takes place — 1 listed sites

University of Cincinnati
Cincinnati, Ohio, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

ClinicalTrials.gov · NCT06099067 · Registry updated: 2024-08-30

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: Sweden
Registry dates and results: Start: 2020-05-15. Completion: 2023-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Canagliflozin (drug)
DPP4 inhibitor (drug)
Liraglutide (drug)
Saxagliptin (drug)
2nd generation Sulfonylurea (drug)

Where the study takes place — 1 listed sites

Research Site
Gothenburg, Sweden
Site recruitment: Not reported

Original record, eligibility, contacts and results →